P1007: PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN JAPANESE PATIENTS WITH POLYCYTHEMIA VERA

• K. Kirito,
• Y. Edahiro,
• K. Ohishi,
• A. Gotoh,
• K. Takenaka,
• H. Shibayama,
• T. Shimizu,
• K. Usuki,
• K. Shimoda,
• M. Ito,
• S. A. VanWart,
• O. Zagrijtschuk,
• A. Qin,
• H. Kawase,
• N. Miyachi,
• T. Sato,
• N. Komatsu

Affiliations

K. Kirito

1 Department of Hematology and Oncology, University of Yamanashi, Chuo-shi, Yamanashi

Y. Edahiro

2 Department of Hematology

K. Ohishi

5 Department of Transfusion Medicine and Cell Therapy, Mie University Hospital, Tsu-shi, Mie

A. Gotoh

6 Department of Hematology, Tokyo Medical University, Shinjuku-ku, Tokyo

K. Takenaka

7 Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon-shi, Ehime

H. Shibayama

8 Department of Hematology, National Hospital Organization Osaka National Hospital, Chuo-ku, Osaka

T. Shimizu

9 Division of Hematology, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo

K. Usuki

10 Department of Hematology, NTT Medical Center Tokyo, Shinagawa-ku, Tokyo

K. Shimoda

11 Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Kiyotake-cho, Miyazaki

M. Ito

12 Department of Pathology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya-shi, Aichi, Japan

S. A. VanWart

13 Enhanced Pharmacodynamics, LLC, NY

O. Zagrijtschuk

14 PharmaEssentia Corporation USA, MA, United States of America

A. Qin

15 PharmaEssentia Corporation, Taipei, Taiwan

H. Kawase

16 PharmaEssentia Japan K.K., Minato-ku, Tokyo, Japan

N. Miyachi

16 PharmaEssentia Japan K.K., Minato-ku, Tokyo, Japan

T. Sato

16 PharmaEssentia Japan K.K., Minato-ku, Tokyo, Japan

N. Komatsu

2 Department of Hematology